ClinicalTrials.gg
WithdrawnNCT06070948Updated Jun 21, 2024

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

A Phase 1 interventional study of Venetoclax in Healthy Volunteers, sponsored by AbbVie. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to assess the bioavailability of two different doses of venetoclax new high drug load formulation tablets relative to two tablets of the currently marketed venetoclax tablets under fed conditions.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Venetoclax
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.
  • A condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG).
  • Participant must be , permanently surgically sterile, or perimenopausal or premenopausal and practicing a method of until at least 1 month after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Regimen A

    Participants will receive venetoclax dose A commercial formulation following a high-fat meal.

    Drug: Venetoclax

  • Experimental
    Regimen B

    Participants will receive venetoclax dose B new formulation following a high-fat meal.

    Drug: Venetoclax

  • Experimental
    Regimen C

    Participants will receive venetoclax dose A new formulation following a high-fat meal.

    Drug: Venetoclax

  • Experimental
    Regimen D

    Participants will receive venetoclax dose B new formulation under fasted conditions.

    Drug: Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Venetoclax

    Cmax of Venetoclax will be assessed.

    Time frame: Up to Day 27

  2. Time to Cmax (Tmax) of Venetoclax

    Tmax of Venetoclax will be assessed.

    Time frame: Up to Day 27

  3. Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUCt) of Venetoclax

    AUCt of Venetoclax will be assessed.

    Time frame: Up to Day 27

  4. AUC from Time 0 to Infinity (AUCinf) of Venetoclax

    AUCinf of Venetoclax will be assessed.

    Time frame: Up to Day 27

  5. Apparent Terminal Phase Elimination Rate Constant (β, BETA) of Venetoclax

    Apparent terminal phase elimination rate constant (β, BETA) of Venetoclax will be assessed.

    Time frame: Up to Day 27

  6. Terminal Phase Elimination Half-life (t1/2) of Venetoclax

    Terminal phase elimination half-life (t1/2) of Venetoclax will be assessed.

    Time frame: Up to Day 27

  7. Number of Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Baseline to Day 57

07

Study locations

1 site
  • Acpru /Id# 259897
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jul 2025, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 6, 2023
StartActual
Oct 5, 2023
Primary completionEst.
Jul 28, 2025
CompletionEst.
Jul 28, 2025
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06070948
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Oct 5, 2023
Primary completion
Jul 28, 2025 (estimated)
Completion
Jul 28, 2025 (estimated)
Last update
Jun 21, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion